• Issue

    Cancer: Volume 129, Issue 20

    15 October 2023


Free Access

Issue Information

  • Pages: 3183-3189
  • First Published: 21 September 2023


Free Access

First person profile: Jedd Wolchok, MD: Advances in treating metastatic melanoma can, in part, be charted by the career of Dr Wolchok, who was on the front lines of investigating immunotherapy science and developed the first immunologic agents to treat melanoma

  • Pages: 3190-3191
  • First Published: 21 September 2023

This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, Jedd Wolchok, MD, was on the front lines of investigating immunotherapy science and developed the first immunologic agents to treat metastatic melanoma. In addition, although cancer deaths are falling globally, there are still substantial variations in mortality by cancer type and geographic location, and genomics rather than care differences drive overall survival rates between men of African ancestry and men of European ancestry with advanced prostate cancer.



Unraveling the “ta-da” moments of implementation in quality improvement

  • Pages: 3213-3215
  • First Published: 18 July 2023

The quality of surgical care has a significant impact on patient outcomes, making it crucial to develop and track surgeon-level performance metrics. Simply tracking these metrics may not be enough; the details of how programs are established and implemented—who were the key participants, what strategies were used, and what were some barriers that the program had to overcome during its implementation process—must be investigated as well.


Open Access

Cancer-associated thrombosis and drug–drug interactions of antithrombotic and antineoplastic agents

  • Pages: 3216-3229
  • First Published: 04 July 2023

Cancer-associated thrombosis is a serious and common complication of cancer. This study offers important insights into the management of cancer-associated thrombosis and the potential drug–drug interactions that can arise when using antithrombotic and antineoplastic agents.


Disease Site

Breast Disease

Open Access

Assessing trends in breast care surveillance metrics after implementing surgeon-specific tracking and performance reporting in a large, integrated cancer network

  • Pages: 3230-3238
  • First Published: 29 June 2023

This study describes the development of a surgeon-specific surveillance metric program for breast surgical care. Substantive changes were seen at the individual surgeon level and institutional level during the first 7 years of implementation.

Chest and Lung Disease

Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non–small cell lung cancer

  • Pages: 3239-3251
  • First Published: 06 June 2023

This study assessed efficacy and safety of pralsetinib in Chinese patients with RET fusion-positive non–small cell lung cancer who had previously received platinum-based chemotherapy (n = 37) or were treatment-naïve (n = 31). Pralsetinib has demonstrated a robust, rapid antitumor activity and an overall well-tolerated safety profile in Chinese patients with RET fusion–positive non–small cell lung cancer.

Genitourinary Disease

The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance

  • Pages: 3252-3262
  • First Published: 17 June 2023

Annual spending attributable to metastatic prostate cancer was $55,949 per person-year in the population covered by commercial insurance and $43,682 in the population covered by employer-sponsored Medicare supplement plans, both in 2019 US dollars. These estimates can improve the precision of value assessments of clinical and policy approaches to the prevention, screening, and treatment of prostate cancer in the United States.

Head and Neck Disease

The protective role of postoperative radiation therapy in low and intermediate grade major salivary gland malignancies: A study of the Canadian Head and Neck Collaborative Research Initiative

  • Pages: 3263-3274
  • First Published: 04 July 2023

This was a retrospective, Canadian-led, international, multi-institutional analysis of 621 patients with low or intermediate grade salivary gland cancer of the parotid or submandibular gland, of whom 309 patients (49.8%) received postoperative radiation therapy. In regression analysis, postoperative radiation therapy was an independent protective factor against locoregional recurrence with an adjusted hazard ratio of 0.53 (95% confidence interval, 0.29–0.97).


Determinants of overall survival in patients with metastatic uveal melanoma

  • Pages: 3275-3286
  • First Published: 29 June 2023

Despite advancements in treatment, metastatic uveal melanoma outcomes remain poor. Female sex, higher baseline performance status, extrahepatic-only metastases, and immune checkpoint therapy are associated with improved survival.



Open Access

Depression, anxiety, and the risk of cancer: An individual participant data meta-analysis

  • Pages: 3287-3299
  • First Published: 07 August 2023

In the present study, individual participant data meta-analyses were conducted to test the associations between anxiety, depression, and the incidence of cancer. Results indicated that depression and anxiety were not associated with an increased risk for cancer, nor when looking at most specific types. The exception to this was lung cancer and smoking-related cancers; however, this association was substantially reduced when adjusting for several health behaviors.

Open Access

Associations between birth defects and childhood and adolescent germ cell tumors according to sex, histologic subtype, and site

  • Pages: 3300-3308
  • First Published: 27 June 2023

We investigated whether birth defects (like congenital heart disease or Down syndrome) are linked to childhood germ cell tumors (GCTs), cancers that mainly develop in the ovaries or testes. We studied different types of birth defects (defects that were caused by chromosome changes like Down syndrome or Klinefelter syndrome, and defects that were not) and different types of GCTs. Only chromosome changes like Down syndrome or Klinefelter syndrome were linked to GCTs. Our study suggests that most children with birth defects are not at increased risk of germ cell tumors, because most birth defects are not caused by chromosome changes.

Groundwater constituents and the incidence of kidney cancer

  • Pages: 3309-3317
  • First Published: 07 June 2023

This study analyzed 180 groundwater exposures in California and used a water-wide association study (WWAS) platform, based on XWAS methodology, to identify associations between groundwater exposures and kidney cancer incidence. Results revealed 13 groundwater constituents meeting stringent WWAS criteria, with seven directly linked to increased kidney cancer incidence, suggesting that public health efforts should consider environmental exposures that may be associated with the incidence of kidney cancer.

Outcomes Research

Open Access

Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021

  • Pages: 3318-3325
  • First Published: 20 June 2023

Although patients aged 65 years and older represent greater than 50% of the global population of patients with cancer, they remain under-represented in clinical trials. Significant differences in progression-free survival and overall survival among patients aged 65 years or older versus those younger than 65 years were uncommon in individual trials, and there was no difference in overall survival after pooling across all studies.

Open Access

Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system

  • Pages: 3326-3333
  • First Published: 30 June 2023

This retrospective, population-based study of 41,735 men undergoing definitive radiation therapy for localized prostate cancer in a national health care delivery system examined survival outcomes with contemporary treatment. In this cohort, survival outcomes, including metastasis-free survival as determined by a novel natural language processing algorithm, are improved compared with historical studies and are comparable to those reported on contemporary clinical trials.


Open Access

Use of electronic cigarettes among African American cancer survivors

  • Pages: 3334-3345
  • First Published: 03 July 2023

The use of electronic cigarettes (e-cigarettes) is becoming more prevalent in the general population, although data are sparse for cancer survivors, particularly African Americans. Here, the authors report estimates of e-cigarette use in African American cancer survivors and note an association with younger age and use of combustible cigarettes. Additionally, for some cancer types, ever use of e-cigarettes may be associated with advanced stage at diagnosis.